PURPOSE: To evaluate the prognostic significance of postchemoradiation pathologic stage and implications for further therapy following preoperative chemoradiation and surgery for advanced/recurrent rectal cancer. METHODS AND MATERIALS: Seventy-seven patients with advanced (fixed or tethered T4) or recurrent rectal cancer were treated with preoperative chemoradation followed by surgical resection of disease. Chemotherapy consisted of either of bolus 5-FU 500 mg/m(2) per day or continuous venous infusion 225 mg/m(2) per day for the duration of radiation. Radiation therapy was planned to be delivered to the whole pelvis to a dose of 45 Gy followed by a boost to the area of the tumor of 5-15 Gy. Total radiation doses ranged from 40 to 63 Gy with a median of 55.8 Gy. Surgical resection was then carried out 6-10 weeks following the completion of treatment (median, 7 weeks). Twenty-eight patients underwent abdominoperineal resection and and 49 patients had sphincter-sparing surgical procedures. None of the patients received postoperative chemotherapy. Follow-up in these patients ranges from 1 year to 8 years with a median of 3 years. RESULTS: Significant downstaging of disease was observed with 12/77 (16%) having no residual disease(pT0) and 13% (10/77) found to have pT1-2, N0 disease, 31% (24/77) with pT3-4, N0 and 40% (31/77) for pT0-4, N1-2 cancers. Survival by pathologic stage was 100% for pT0-2, N0 cancers, 80% for pT3-4, N0 and 73% for pTx, N1-2. Local recurrence of disease was observed in 0% of patients with pT0-2, N0 as compared with 13% (3/24) in pT3-4, N0 and 16% (5/31) in pT0-4, N1-2 patients. CONCLUSION: Downstaging following preoperative chemoradiation is a significant prognostic factor. Patients with pT0, T1, or T2 disease have an excellent prognosis and are unlikely to fail locally or with systemic disease. However, patient with T3/T4 or N+ disease may benefit from further adjuvant chemotherapy.
PURPOSE: To evaluate the prognostic significance of postchemoradiation pathologic stage and implications for further therapy following preoperative chemoradiation and surgery for advanced/recurrent rectal cancer. METHODS AND MATERIALS: Seventy-seven patients with advanced (fixed or tethered T4) or recurrent rectal cancer were treated with preoperative chemoradation followed by surgical resection of disease. Chemotherapy consisted of either of bolus 5-FU 500 mg/m(2) per day or continuous venous infusion 225 mg/m(2) per day for the duration of radiation. Radiation therapy was planned to be delivered to the whole pelvis to a dose of 45 Gy followed by a boost to the area of the tumor of 5-15 Gy. Total radiation doses ranged from 40 to 63 Gy with a median of 55.8 Gy. Surgical resection was then carried out 6-10 weeks following the completion of treatment (median, 7 weeks). Twenty-eight patients underwent abdominoperineal resection and and 49 patients had sphincter-sparing surgical procedures. None of the patients received postoperative chemotherapy. Follow-up in these patients ranges from 1 year to 8 years with a median of 3 years. RESULTS: Significant downstaging of disease was observed with 12/77 (16%) having no residual disease(pT0) and 13% (10/77) found to have pT1-2, N0 disease, 31% (24/77) with pT3-4, N0 and 40% (31/77) for pT0-4, N1-2 cancers. Survival by pathologic stage was 100% for pT0-2, N0 cancers, 80% for pT3-4, N0 and 73% for pTx, N1-2. Local recurrence of disease was observed in 0% of patients with pT0-2, N0 as compared with 13% (3/24) in pT3-4, N0 and 16% (5/31) in pT0-4, N1-2 patients. CONCLUSION: Downstaging following preoperative chemoradiation is a significant prognostic factor. Patients with pT0, T1, or T2 disease have an excellent prognosis and are unlikely to fail locally or with systemic disease. However, patient with T3/T4 or N+ disease may benefit from further adjuvant chemotherapy.
Authors: Runjan Chetty; Pelvender Gill; Dhirendra Govender; Adrian Bateman; Hee Jin Chang; David Driman; Fraser Duthie; Marisa Gomez; Eleanor Jaynes; Cheok Soon Lee; Michael Locketz; Claudia Mescoli; Corwyn Rowsell; Anne Rullier; Stefano Serra; Neil Shepherd; Eva Szentgyorgyi; Rajkumar Vajpeyi; Lai Mun Wang Journal: Virchows Arch Date: 2012-01-13 Impact factor: 4.064
Authors: Benjamin R Tan; Fabienne Thomas; Robert J Myerson; Barbara Zehnbauer; Kathryn Trinkaus; Robert S Malyapa; Matthew G Mutch; Elliot E Abbey; Amer Alyasiry; James W Fleshman; Howard L McLeod Journal: J Clin Oncol Date: 2011-01-04 Impact factor: 44.544
Authors: Xabier García-Albéniz; Rosa Gallego; Ralf Dieter Hofheinz; Gloria Fernández-Esparrach; Juan Ramón Ayuso-Colella; Josep Antoni Bombí; Carles Conill; Miriam Cuatrecasas; Salvadora Delgado; Angels Ginés; Rosa Miquel; Mario Pagés; Estela Pineda; Verónica Pereira; Aarón Sosa; Oscar Reig; Iván Victoria; Luis Feliz; Antonio María de Lacy; Antoni Castells; Iris Burkholder; Andreas Hochhaus; Joan Maurel Journal: World J Gastroenterol Date: 2014-11-14 Impact factor: 5.742
Authors: R Hughes; R Glynne-Jones; J Grainger; P Richman; A Makris; M Harrison; R Ashford; R A Harrison; J I Livingstone; P J McDonald; J Meyrick Thomas; I C Mitchell; J M A Northover; R Phillips; M Wallace; A Windsor; J R Novell Journal: Int J Colorectal Dis Date: 2005-04-30 Impact factor: 2.571
Authors: Dietmar Ofner; Alexander F Devries; Renate Schaberl-Moser; Richard Greil; Hans Rabl; Jörg Tschmelitsch; Matthias Zitt; Karin S Kapp; Gerd Fastner; Felix Keil; Wolfgang Eisterer; Robert Jäger; Felix Offner; Michael Gnant; Josef Thaler Journal: Strahlenther Onkol Date: 2011-01-21 Impact factor: 3.621
Authors: Jose G Guillem; David B Chessin; Alfred M Cohen; Jinru Shia; Madhu Mazumdar; Warren Enker; Philip B Paty; Martin R Weiser; David Klimstra; Leonard Saltz; Bruce D Minsky; W Douglas Wong Journal: Ann Surg Date: 2005-05 Impact factor: 12.969
Authors: Leonard L Gunderson; John Milburn Jessup; Daniel J Sargent; Frederick L Greene; Andrew Stewart Journal: J Clin Oncol Date: 2009-11-30 Impact factor: 44.544